Fig. 2

Progression-free survival (PFS). PFS is shown for patients treated with mFOLFOX-6 plus cetuximab (FOLFOX + Cmab) or XELOX plus cetuximab (XELOX + Cmab). A log-rank test did not reveal any significant differences in PFS between the two groups (P = 0.99)